This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-05-03 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-05-03 | IntroReferral | Introduced in House | Library of Congress |